Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Malignant Rhabdoid Tumor (MRT): early-phase trial registry

1 of 1 indexed Malignant Rhabdoid Tumor (MRT) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Malignant Rhabdoid Tumor (MRT): 1 US clinical trial tracked, 1 recruiting.

Malignant Rhabdoid Tumor (MRT) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Susan Chi, MD, running 1 of these trials.

Enrollment posture brief

Registry condition malignant-rhabdoid-tumor-mrt

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Malignant Rhabdoid Tumor (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Malignant Rhabdoid Tumor (MRT)

Malignant Rhabdoid Tumor (MRT) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignant Rhabdoid Tumor (MRT) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignant Rhabdoid Tumor (MRT) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Susan Chi, MD 1 trials

Named interventions

Most-linked intervention names on Malignant Rhabdoid Tumor (MRT) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tazemetostat Drug
1 trials
Ipilimumab Drug
1 trials
Nivolumab Drug
1 trials

US sites by state

Facility locations filed on Malignant Rhabdoid Tumor (MRT) trials. A trial with sites in several states counts in each.

Texas 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignant Rhabdoid Tumor (MRT) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Malignant Rhabdoid Tumor (MRT) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Susan Chi, MD sponsors the most Malignant Rhabdoid Tumor (MRT) trials on record, review their full trial history before evaluating a specific study. See Susan Chi, MD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Rhabdoid Tumor (MRT) condition card totals 1 registered trials; most-linked intervention Tazemetostat; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.